Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hammerer

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
European Urology|December 12, 2003
pT0 after radical prostatectomy: overtreatment for insignificant prostate cancer?Peter Hammerer
Aktuelle Urologie|November 30, 2021
Heidrun Rexer, Peter Hammerer
BJU International|March 1, 2013
Reply: Landmarks in hormonal therapy for prostate cancerPeter Hammerer, Stephan Madersbacher
BJU International|October 11, 2012
Landmarks in hormonal therapy for prostate cancerPeter Hammerer, Stephan Madersbacher
Aktuelle Urologie|March 20, 2020
[Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago]Peter Hammerer, Walther Grohmann, Axel S Merseburger
European Urology|June 20, 2003
Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?M Kuczyk, Levent Turkeri, Peter Hammerer, et al.
World Journal of Urology|March 19, 2016
Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical managementFrancois Rozet, Thierry Roumeguère, Martin Spahn, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
European Urology|November 26, 2008
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature reviewAntonio Alcaraz, Peter Hammerer, Andrea Tubaro, et al.
European Urology|February 5, 2003
Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?Martin G Friedrich, Angelika Hellstern, Marieta I Toma, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
European Urology|December 12, 2003
pT0 after radical prostatectomy: overtreatment for insignificant prostate cancer?Peter Hammerer
Aktuelle Urologie|November 30, 2021
Heidrun Rexer, Peter Hammerer
BJU International|March 1, 2013
Reply: Landmarks in hormonal therapy for prostate cancerPeter Hammerer, Stephan Madersbacher
BJU International|October 11, 2012
Landmarks in hormonal therapy for prostate cancerPeter Hammerer, Stephan Madersbacher
Aktuelle Urologie|March 20, 2020
[Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago]Peter Hammerer, Walther Grohmann, Axel S Merseburger
European Urology|June 20, 2003
Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?M Kuczyk, Levent Turkeri, Peter Hammerer, et al.
World Journal of Urology|March 19, 2016
Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical managementFrancois Rozet, Thierry Roumeguère, Martin Spahn, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
European Urology|November 26, 2008
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature reviewAntonio Alcaraz, Peter Hammerer, Andrea Tubaro, et al.
European Urology|February 5, 2003
Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?Martin G Friedrich, Angelika Hellstern, Marieta I Toma, et al.
Pageof 6